Gil Blum
Stock Analyst at Needham
(3.97)
# 661
Out of 5,182 analysts
432
Total ratings
40.83%
Success rate
14.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Initiates: Buy | $44 | $23.70 | +85.65% | 1 | Apr 10, 2026 | |
| AUTL Autolus Therapeutics | Reiterates: Buy | $10 | $1.61 | +521.12% | 36 | Apr 9, 2026 | |
| NRIX Nurix Therapeutics | Reiterates: Buy | $26 | $16.69 | +55.78% | 30 | Apr 8, 2026 | |
| ABSI Absci | Reiterates: Buy | $7 | $3.23 | +116.72% | 10 | Mar 30, 2026 | |
| CELC Celcuity | Reiterates: Buy | $122 | $125.25 | -2.59% | 24 | Mar 26, 2026 | |
| ARTV Artiva Biotherapeutics | Reiterates: Buy | $18 | $12.11 | +48.64% | 8 | Mar 11, 2026 | |
| IMCR Immunocore Holdings | Maintains: Buy | $71 → $75 | $31.38 | +139.01% | 15 | Feb 26, 2026 | |
| ACLX Arcellx | Downgrades: Hold | n/a | $115.10 | - | 26 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $80 → $82 | $55.72 | +47.16% | 28 | Feb 13, 2026 | |
| MREO Mereo BioPharma Group | Maintains: Buy | $5 → $3 | $0.33 | +819.40% | 21 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $1.69 | +255.03% | 23 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $11 | $2.80 | +292.86% | 19 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | n/a | $21.17 | - | 39 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $8.39 | +126.46% | 4 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $5.95 | +101.68% | 33 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $6.38 | +558.31% | 17 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.60 | +122.22% | 26 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $14.45 | - | 8 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $6 | $1.08 | +455.56% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.37 | - | 9 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | n/a | $3.90 | - | 22 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $7.35 | - | 16 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $11.00 | +336.36% | 9 | Aug 2, 2024 |
Lyell Immunopharma
Apr 10, 2026
Initiates: Buy
Price Target: $44
Current: $23.70
Upside: +85.65%
Autolus Therapeutics
Apr 9, 2026
Reiterates: Buy
Price Target: $10
Current: $1.61
Upside: +521.12%
Nurix Therapeutics
Apr 8, 2026
Reiterates: Buy
Price Target: $26
Current: $16.69
Upside: +55.78%
Absci
Mar 30, 2026
Reiterates: Buy
Price Target: $7
Current: $3.23
Upside: +116.72%
Celcuity
Mar 26, 2026
Reiterates: Buy
Price Target: $122
Current: $125.25
Upside: -2.59%
Artiva Biotherapeutics
Mar 11, 2026
Reiterates: Buy
Price Target: $18
Current: $12.11
Upside: +48.64%
Immunocore Holdings
Feb 26, 2026
Maintains: Buy
Price Target: $71 → $75
Current: $31.38
Upside: +139.01%
Arcellx
Feb 23, 2026
Downgrades: Hold
Price Target: n/a
Current: $115.10
Upside: -
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Buy
Price Target: $80 → $82
Current: $55.72
Upside: +47.16%
Mereo BioPharma Group
Jan 13, 2026
Maintains: Buy
Price Target: $5 → $3
Current: $0.33
Upside: +819.40%
Aug 9, 2024
Reiterates: Buy
Price Target: $6
Current: $1.69
Upside: +255.03%
Mar 26, 2026
Maintains: Buy
Price Target: $10 → $11
Current: $2.80
Upside: +292.86%
Mar 26, 2026
Reiterates: Underperform
Price Target: n/a
Current: $21.17
Upside: -
Mar 20, 2026
Reiterates: Buy
Price Target: $19
Current: $8.39
Upside: +126.46%
Mar 19, 2026
Maintains: Buy
Price Target: $10 → $12
Current: $5.95
Upside: +101.68%
Mar 9, 2026
Reiterates: Buy
Price Target: $42
Current: $6.38
Upside: +558.31%
Feb 26, 2026
Reiterates: Buy
Price Target: $8
Current: $3.60
Upside: +122.22%
Dec 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $14.45
Upside: -
Nov 4, 2025
Maintains: Buy
Price Target: $9 → $6
Current: $1.08
Upside: +455.56%
Oct 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.37
Upside: -
Jul 24, 2025
Maintains: Hold
Price Target: n/a
Current: $3.90
Upside: -
Mar 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $7.35
Upside: -
Aug 2, 2024
Reiterates: Buy
Price Target: $48
Current: $11.00
Upside: +336.36%